ERBB2 and breast carcinoma: Meanwhile, recent studies have reported that HER2-low breast cancer might benefit from HER2-targeted antibody-drug conjugates (ADCs) treatment [7,12], such as trastuzumab deruxtecan (T-Dxd) [13] and trastuzumab duocarmazine (SYD985) [14].